Janux Therapeutics (NASDAQ:JANX – Get Free Report) and Vericel (NASDAQ:VCEL – Get Free Report) are both healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, risk, dividends, analyst recommendations, earnings, institutional ownership and profitability.
Risk and Volatility
Janux Therapeutics has a beta of 2.44, indicating that its share price is 144% more volatile than the S&P 500. Comparatively, Vericel has a beta of 1.08, indicating that its share price is 8% more volatile than the S&P 500.
Analyst Ratings
This is a summary of recent ratings for Janux Therapeutics and Vericel, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Janux Therapeutics | 2 | 3 | 10 | 1 | 2.62 |
| Vericel | 0 | 1 | 5 | 1 | 3.00 |
Janux Therapeutics presently has a consensus price target of $36.92, indicating a potential upside of 224.74%. Vericel has a consensus price target of $62.00, indicating a potential upside of 8.85%. Given Janux Therapeutics’ higher possible upside, analysts clearly believe Janux Therapeutics is more favorable than Vericel.
Profitability
This table compares Janux Therapeutics and Vericel’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Janux Therapeutics | N/A | -11.80% | -10.97% |
| Vericel | 10.27% | 9.09% | 6.68% |
Insider and Institutional Ownership
75.4% of Janux Therapeutics shares are owned by institutional investors. 7.9% of Janux Therapeutics shares are owned by company insiders. Comparatively, 7.6% of Vericel shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Valuation and Earnings
This table compares Janux Therapeutics and Vericel”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Janux Therapeutics | $10.00 million | 69.56 | -$113.62 million | ($1.59) | -7.15 |
| Vericel | $276.26 million | 10.52 | $16.52 million | $0.64 | 89.00 |
Vericel has higher revenue and earnings than Janux Therapeutics. Janux Therapeutics is trading at a lower price-to-earnings ratio than Vericel, indicating that it is currently the more affordable of the two stocks.
Summary
Vericel beats Janux Therapeutics on 8 of the 14 factors compared between the two stocks.
About Janux Therapeutics
Janux Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing immunotherapies for cancer. The company’s research focuses on engaging a patient’s T cells to recognize and attack tumors. Janux’s proprietary platforms are designed to keep certain immune therapies inactive until they reach the tumor environment, with the goal of limiting activity in healthy tissues. Its clinical-stage programs include candidates directed at targets such as PSMA and EGFR, and its broader pipeline includes additional investigational cancer therapies.
About Vericel
Vericel Corporation is a biopharmaceutical company focused on developing and commercializing cell therapies and other treatments for serious conditions. Based in Cambridge, Massachusetts, the company markets its products primarily in the United States. Its products include MACI, an implant made from a patient’s own cultured cartilage cells used to repair certain cartilage defects in the knee, and Epicel, a cultured skin graft used to treat patients with deep burns. Vericel also commercializes NexoBrid in the United States, an enzyme-based treatment for removing dead tissue from severe thermal burns.
Receive News & Ratings for Janux Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Janux Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
